Ultra low dose recombinant IL-2 in Hepatitis C Virus Disease

$0M01FY2000RRNIH

Weill Medical College Of Cornell Univ, New York NY

Investigators

Linked publications & trials

Paper 31039789 Paper 30766724 Paper 30766720 Paper 30420708 Paper 28499385 Paper 28399044 Paper 28159195 Paper 28091527 Paper 28041591 Paper 27575936 Paper 27077672 Paper 26416876 Paper 26094935 Paper 25109932 Paper 25063537 Paper 25043989 Paper 24756957 Paper 24526575 Paper 24360764 Paper 24303604 Paper 24144899 Paper 23944767 Paper 23871337 Paper 23801897 Paper 23744404 Paper 23593417 Paper 23223343 Paper 23063139 Paper 22853972 Paper 22834729 Paper 22806462 Paper 22770936 Paper 22669298 Paper 22456045 Paper 22293431 Paper 22277138 Paper 22258490 Paper 22235819 Paper 22208413 Paper 22207511 Paper 21941167 Paper 21940153 Paper 21873564 Paper 21631966 Paper 21570269 Paper 21558955 Paper 21554737 Paper 21293986 Paper 21097142 Paper 21096136 Paper 21041700 Paper 20965292 Paper 20962315 Paper 20871389 Paper 20825306 Paper 20719107 Paper 20650002 Paper 20569715 Paper 20467286 Paper 20407273 Paper 20360190 Paper 20237308 Paper 20217365 Paper 20200483 Paper 20155836 Paper 20148867 Paper 20016779 Paper 19954851 Paper 19950191 Paper 19844184 Paper 19800772 Paper 19768163 Paper 19720957 Paper 19576355 Paper 19417580 Paper 19414076 Paper 19346372 Paper 19279557 Paper 19220493 Paper 19194319 Paper 19191590 Paper 19163084 Paper 19114860 Paper 19018785 Paper 18937333 Paper 18832735 Paper 18810712 Paper 18798334 Paper 18796618 Paper 18772065 Paper 18753121 Paper 18703989 Paper 18698223 Paper 18674890 Paper 18647233 Paper 18572755 Paper 18558886 Paper 18556968 Paper 18556967 Paper 18480202

Abstract

The primary objective of this study is to determine whether interleukin-2 (IL-2) can be of additive benefit in the treatment of chronic hepatitis due to Hepatitis C Virus (HCV). Secondary objectives are to evaluate the immune response to HCV in the presence and absence of IL-2 therapy.

View original record on NIH RePORTER →